AZD 9668

Drug Profile

AZD 9668

Alternative Names: AZD9668

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator AstraZeneca
  • Developer Allegheny Singer Research Institute; AstraZeneca; National Cancer Institute (USA)
  • Class Bronchodilators
  • Mechanism of Action Leucocyte elastase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Type 2 diabetes mellitus
  • Phase I/II Bronchiolitis obliterans
  • Discontinued Bronchiectasis; Chronic obstructive pulmonary disease; Cystic fibrosis

Most Recent Events

  • 15 Dec 2016 Biomarkers information updated
  • 01 Jan 2016 Phase-I/II clinical trials in Bronchiolitis Obliterans (Treatment-experienced) in USA (PO) (NCT02669251)
  • 14 Nov 2015 AstraZeneca, National Institutes of Health, University of Pittsburgh and University of South Florida plan a phase II trial for Type-2 diabetes mellitus (In adults, In the elderly, Adjunctive treatment) in USA (PO) (NCT02597101)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top